One of the main challenges is the high affinity of KRAS for GTP and GDP, making it difficult to disrupt its activity. Additionally, KRAS mutations vary significantly between different patients and cancer types, requiring personalized approaches. Resistance to KRAS inhibitors can also develop, necessitating combination therapies and ongoing research to overcome these obstacles.
